Botanix Pharmaceuticals Limited (ASX: $BOT) has requested an immediate trading halt in its securities pending the release of an announcement concerning FDA-approval for Sofdraâ„¢. The trading halt is expected to remain in place until the announcement is made, anticipated no later than the open of trading on Friday, 21 June 2024.
The Directors of Botanix Pharmaceuticals Limited have requested the trading halt in order to facilitate the release of an important announcement regarding the FDA-approval for Sofdraâ„¢. The Company is committed to ensuring that the market is informed in a timely manner and believes that the trading halt is necessary to achieve this. We look forward to providing further details upon the release of the announcement.
Botanix Pharmaceuticals (ASX: $BOT) has requested a trading halt in anticipation of an imminent announcement regarding the FDA-approval for Sofdraâ„¢. The Company aims to keep the market informed and plans to release the announcement no later than the open of trading on Friday, 21 June 2024. This move reflects Botanix's commitment to transparency and timely dissemination of significant developments. The forthcoming announcement is expected to provide valuable insights into the Company's future prospects and strategic direction.